Skip to main content
. 2013 Feb 20;2013:487143. doi: 10.1155/2013/487143

Table 6.

The comparison of the prevalence of adverse effects (episodes per 100 samples) between both groups.

Adverse events (AEs) Prevalence of events (%) Between-group P value
DSG* DRSP*
Nausea/vomiting 8 (17.8) 1 (2.2) NS
Dizziness 1 (2.2) 4 (8.9) NS
Amenorrhea 3 (6.7) 1 (2.2) NS
Spotting 2 (4.4) 2 (4.4) NS
Mastalgia 1 (2.2) 0 (0) NS

 *DSG: desogestrel group and DRSP: drospirenone group.